123p 5.0 4.2%
Last Trade - 20/01/21
| Market Cap | ÂŁ155.0m |
| Enterprise Value | ÂŁ146.1m |
| Revenue | ÂŁ486k |
| Position in Universe | 883rd / 1804 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.21 | 15.4 | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally select those bacteria that have a precise and evolved therapeutic effect. Its MicroRx methodology offers a pipeline of approximately 10 therapeutic programs covering autoimmune diseases, central nervous system (CNS) disorders and cancer. The Company uses MicroRx to develop its programs into the clinic and has approximately two programs in patient trials. The Company focuses on immune conditions, such as pediatric Crohn's, pediatric colitis and irritable bowel syndrome.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | January 10, 2014 |
| Public Since | February 18, 2014 |
| No. of Shareholders: | n/a |
| No. of Employees: | 127 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 131,392,242 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 9 Bond Court, LEEDS, LS1 2JZ, United Kingdom |
| Web | https://www.4dpharmaplc.com/ |
| Phone | +44 113 8950130 |
| Contact | () |
| Auditors | RSM UK Audit LLP |
As of 20/01/21, shares in 4D Pharma are trading at 123p, giving the company a market capitalisation of ÂŁ155.0m. This share price information is delayed by 15 minutes.
Shares in 4D Pharma are currently trading at 123p and the price has moved by 18% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the 4D Pharma price has moved by 31.2% over the past year.
Of the analysts with advisory recommendations for 4D Pharma, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for 4D Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
4D Pharma is scheduled to issue upcoming financial results on the following dates:
4D Pharma does not currently pay a dividend.
4D Pharma does not currently pay a dividend.
4D Pharma does not currently pay a dividend.
To buy shares in 4D Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in 4D Pharma are currently trading at 123p, giving the company a market capitalisation of ÂŁ155.0m.
Here are the trading details for 4D Pharma:
Based on an overall assessment of its quality, value and momentum, 4D Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in 4D Pharma are currently priced at 123p. At that level they are trading at 0.263% discount to the analyst consensus target price of 123.32.
Analysts covering 4D Pharma currently have a consensus Earnings Per Share (EPS) forecast of -0.194 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4D Pharma. Over the past six months, the relative strength of its shares against the market has been 0.122k%. At the current price of 123p, shares in 4D Pharma are trading at 38.44% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for 4D Pharma.
4D Pharma's management team is headed by:
Here are the top five shareholders of 4D Pharma based on the size of their shareholding:
